Troy Rafferty Instrumental in $80 Million Settlement for Plaintiffs in Actos Litigation

In another major legal victory, Troy Rafferty was instrumental in securing an $80 million settlement on behalf of plaintiffs who suffered severe health complications after taking the diabetes drug Actos. The plaintiffs in this case alleged that Takeda Pharmaceuticals, the manufacturer of Actos, failed to adequately warn patients and healthcare providers about the increased risk of bladder cancer associated with long-term use of the drug.

Rafferty represented hundreds of individuals who had been diagnosed with bladder cancer after taking Actos to manage their Type 2 diabetes. Through rigorous investigation, Rafferty and his team uncovered internal documents showing that Takeda was aware of the heightened cancer risk but chose to keep this information from the public in order to protect its profits.

The $80 million settlement provided compensation to the victims of Takeda’s negligence and served as a critical reminder of the responsibility that pharmaceutical companies have to be transparent about the risks associated with their products. This case highlighted the dangers of prioritizing profits over patient safety and reaffirmed the importance of corporate accountability in the pharmaceutical industry.

For more information on the Actos litigation, learn more about the settlement here.